Sale!

COL11A2 Gene Deafness Autosomal Dominant Type 13 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The COL11A2 gene plays a crucial role in the production of a specific type of collagen, which is essential for the proper development and maintenance of structures within the ear. Mutations in the COL11A2 gene are associated with autosomal dominant non-syndromic hearing loss, specifically categorized as Deafness, Autosomal Dominant Type 13 (DFNA13). This condition is characterized by the progressive loss of hearing, which typically begins in childhood or early adulthood.

To diagnose this specific genetic cause of hearing loss, DNA Labs UAE offers a genetic test that targets the COL11A2 gene. This test is designed to identify mutations within the gene that are known to result in DFNA13. It is a crucial tool for families with a history of hearing loss, as it can provide a definitive diagnosis, guide treatment decisions, and inform family planning.

The test is priced at 4400 AED and involves collecting a DNA sample, usually through a blood draw or a cheek swab. The sample is then analyzed in the laboratory for the presence of mutations in the COL11A2 gene. Results from the test can help in understanding the genetic basis of hearing loss in affected individuals and facilitate genetic counseling for the family. It is important for potential patients to consult with a healthcare provider or a genetic counselor before and after undergoing genetic testing to fully understand the implications of the test results.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

COL11A2 Gene Deafness Autosomal Dominant Type 13 Genetic Test

Welcome to DNA Labs UAE, where we offer the COL11A2 Gene Deafness Autosomal Dominant Type 13 Genetic Test. This test can help diagnose individuals with a specific form of deafness known as autosomal dominant type 13.

Test Components

The test includes the following components:

  • COL11A2 Gene Deafness autosomal dominant type 13 Genetic Test

Price

The cost of the test is 4400.0 AED.

Sample Condition

The test requires either a blood sample, extracted DNA, or one drop of blood on an FTA card.

Report Delivery

The test results will be delivered within 3 to 4 weeks.

Method

The test utilizes NGS (Next-Generation Sequencing) technology to analyze multiple genes simultaneously and identify any genetic variations or mutations.

Test Type

The test is specifically designed for individuals with Ear Nose Throat Disorders.

Doctor

The test is conducted under the supervision of an ENT Doctor.

Test Department

The test is performed in the Genetics department.

Pre Test Information

Prior to the test, it is important to provide the clinical history of the patient who is going for the PTPN23 Gene Ciliogenesis related disorder NGS Genetic DNA Test. A Genetic Counselling session may also be conducted to draw a pedigree chart of family members affected with the PTPN23 Gene Ciliogenesis related disorder NGS Genetic DNA Test gene PTPN24.

Test Details

The COL11A2 gene is associated with autosomal dominant type 13 deafness. This means that an individual only needs to inherit one copy of the mutated gene from either parent to develop the condition. The NGS genetic test specifically looks for mutations or variations in the COL11A2 gene that may be causing or contributing to the individual’s hearing loss. By identifying the specific genetic mutation, the test can provide valuable information for diagnosis, prognosis, and potential treatment options. It can also assist with genetic counseling and family planning decisions.

Test Name COL11A2 Gene Deafness autosomal dominant type 13 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Ear Nose Throat Disorders
Doctor ENT Doctor
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for PTPN23 Gene Ciliogenesis related disorder NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with PTPN23 Gene Ciliogenesis related disorder NGS Genetic DNA Test gene PTPN24
Test Details

The COL11A2 gene is associated with a form of deafness known as autosomal dominant type 13. Autosomal dominant means that an individual only needs to inherit one copy of the mutated gene from either parent to develop the condition.

NGS (Next-Generation Sequencing) genetic testing is a method used to analyze multiple genes simultaneously to identify any genetic variations or mutations that may be present. In the case of COL11A2 gene deafness, an NGS genetic test would specifically look for mutations or variations in the COL11A2 gene that may be causing or contributing to the individual’s hearing loss.

By identifying the specific genetic mutation, NGS testing can provide valuable information for diagnosis, prognosis, and potential treatment options for individuals with autosomal dominant type 13 deafness. It can also help with genetic counseling and family planning decisions.